Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for early high-risk primary IgA nephropathy
ChiCTR2200066031Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sirolimus in IgA nephropathy (IgAN), sponsored by Peking Union Medical College Hospital. Primary endpoints: Serum creatinine, 24-hour urine protein and 2 more. Started Nov 2022; status: recruiting.
02
Drugs
sirolimus
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2200066031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066031.